15 results about "Oncocyte" patented technology

2-diarylmethyl-4-aminotetrahydropyran derivatives are disclosed. The compounds include the following genus:or a pharmaceutically acceptable salt thereof. The compounds activate cellular PP2A, suppress oncogenic kinase signaling and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

The present invention relates to a modified mitochondrial comprising, on the outer membrane of the mitochondrial, an antibody that binds to a cancer cell-specific protein and a cytosine deaminase. It is proved that when the mitochondria and 5-FC are jointly used for treating a pancreatic cancer cell line, the cytotoxicity induced by 5-FC treatment is remarkably enhanced. The effect is proved as follows: 5-FC is converted into 5-FU by cytosine deaminase expressed on a mitochondrial outer membrane, so that pancreatic cancer cells are induced to generate apoptosis. Therefore, the modified mitochondria according to the present invention can be effectively used in anticancer therapy using 5-FC as an anticancer agent.

The present application relates to the application of ocanin in the preparation of anti-tumor drugs, and the ocanin is used in the anti-tumor drugs alone or in combination with 5-fluorouracil, and the concentration of the ocanin used in the preparation of anti-intestinal cancer drugs is 20-500 uMol. It is found that the ocanin can inhibit the growth of intestinal cancer cells in vivo and in vitro, and the naked mice have good tolerance to the natural compound. The ocanin has better anti-intestinal cancer effect than other extracts of goldeneye and devil's needle, and has better anti-cancer effect and smaller toxicity than the current conventional intestinal cancer drug 5-fluorouracil. Therefore, the ocanin can be developed into a new anti-cancer drug.

2-diarylmethyl-4-aminotetrahydropyran derivatives are disclosed. The compounds include the following genus:or a pharmaceutically acceptable salt thereof.The compounds activate cellular PP2A, suppress oncogenic kinase signaling and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

The invention relates to application of theaflavin as a UGP2 inhibitor and application of theaflavin in preparation of a medicine for preventing and / or treating hepatocellular carcinoma, and belongs to the technical field of biology. According to the invention, the monomeric compound theaflavin derived from a natural product can be used as a UGP2 direct targeting inhibitor for the first time, and is used for preparing a liver cancer treatment medicine for regulating and controlling glucose metabolism reprogramming. The theaflavin can be specifically and directly combined at a UGP2 active site in a targeting manner through high activity to inhibit the activity of the UGP2, is the first specific inhibitor which takes the UGP2 as a target spot and is reported at present, and can be used for remarkably inhibiting tumor phenotypes such as proliferation, migration and invasion of liver cancer cells by inhibiting UGP2-mediated UDPG synthesis and intracellular glycogen accumulation.

The present invention relates to gene editing agents (e.g., CRISPR / Cas) that target mutated oncogenes (e.g., a mutated oncogene a cancer is addicted to) and uses thereof (e.g., for inactivation of mutated oncogenes and / or treatment cancer). In some embodiments, the mutated oncogene is a mutated KRAS. In some embodiments, the cancer is pancreatic ductal adenocarcinoma, non-small cell lung cell, or colorectal cancer.

The invention discloses application of a reagent for detecting or inhibiting a TCF7L2-Exon14 shear isomer and an oral cancer treatment medicine, and belongs to the technical field of tumor molecular biology. According to the invention, the expression condition of the TCF7L2-Exon14 shear isomer is detected in normal oral mucosa epithelial cells and oral cancer cells by using a semi-quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction) technology. The result shows that compared with normal oral mucosa epithelial cells, the expression of the TCF7L2-Exon14 shear isomer in oral cancer tissues is obviously improved. Therefore, the TCF7L2-Exon14 shear isomer is highly expressed in oral cancer tissues, possibly has an important biological function for occurrence and development of oral cancer, and can be used as an oral cancer diagnosis molecular marker and a treatment target.

The invention belongs to the technical field of medical biology, and particularly relates to application of IGFBP7 in preparation of a medicine for treating gastric adenocarcinoma. IGFBP7 closely related to gastric adenocarcinoma is screened out as a molecular marker through multiple bioinformatics technologies, expression of IGFBP7 in gastric adenocarcinoma is detected through immunohistochemistry, and prognosis of a patient is evaluated by establishing a scoring system combining dyeing intensity and positive cell proportion. Experimental results show that IGFBP7 knock-down can effectively inhibit proliferation and migration of gastric adenocarcinoma cells, induce apoptosis and trigger S-phase arrest. Furthermore, a co-culture experiment of gastric adenocarcinoma cells and mononuclear cells reveals that IGFBP7 can promote polarization of M2 type macrophages in a gastric adenocarcinoma tumor immune microenvironment.

The invention provides an application of Mito-apocynin in preparation of a medicine for treating liver cancer. It is found for the first time that Mito-apocynin has remarkable anti-hepatoma activity, oxidative stress is induced to generate a large amount of reactive oxygen species (ROS) to trigger oxidative stress by targeting mitochondria, namely a cell energy factory and an apoptosis control center, high-level ROS induces hepatoma cell apoptosis, proliferation of hepatoma cells is effectively inhibited, and therefore hepatoma cells are effectively killed.

A pharmaceutical composition includes: (a) a targeting agent for cancer cell mitochondria, (b) an ion chelating agent, and (c) pharmacologically active multivalent ions. The weight ratio of (a) is 64.5%˜43.7% based on the total weight of the pharmaceutical composition, the weight ratio of (b) is 56.2%˜16.1% based on the total weight of the pharmaceutical composition; the weight ratio of (c) is 19.4%˜0.000116% based on the total weight of the pharmaceutical composition.

The invention discloses application of shPPIA in preparation of a molecular targeted therapeutic drug for inhibiting gastric cancer progression, and relates to the technical field of biomedicine.The drug inhibits gastric cancer cell proliferation by down-regulating the expression level of shPPIA, and the drug inhibits eEF1A1 protein stability by inhibiting PPIA expression, reduces nuclear translocation of eEF1A1 protein, inhibits eEF1A1-MDM2 interaction and up-regulates p53 protein expression by down-regulating eEF1A1 protein stability by down-regulating eEF1A1 protein stability by down-regulating eEF1A1 protein nuclear translocation by down-regulating eEF1A1 protein expression by down-regulating eEF1A1 protein expression; the medicine is used for inhibiting proliferation, migration or invasion of gastric cancer cells and / or promoting apoptosis of the gastric cancer cells. According to the application, shPPIA is provided through in-vitro and in-vivo experiments to serve as evidence of a new therapeutic target, a cancer promoting mechanism of a PPIA-eEF1A1-MDM2-p53 signal axis is disclosed, the problem that an existing targeted drug is insufficient in curative effect is solved through the provided composition, proliferation and metastasis of gastric cancer cells can be effectively inhibited, and a new clinical transformation strategy is provided for gene therapy of gastric cancer.

The invention belongs to the technical field of organic synthesis, and provides a mitochondrial targeting and viscosity-sensitive near-infrared fluorescent probe as well as a preparation method and application thereof. The fluorescent probe has positive charges, can be selectively enriched in mitochondria, and can dynamically monitor the viscosity of the mitochondria. The synthesis steps of the probe are short, and post-treatment is easy; the selectivity, the sensitivity and the stability are high. The excitation wavelength and the emission wavelength are in a near-infrared region, so that biological autofluorescence interference can be effectively avoided, and deep tissue penetration potential is achieved. The probe has been successfully applied to real-time monitoring of mitochondrial viscosity level in cancer cell autophagy and apoptosis processes and detection of viscosity change in zebrafish under nystatin stimulation. The invention provides an efficient tool for dynamic monitoring of mitochondrial viscosity, has important application value in the aspects of early diagnosis, efficacy evaluation and the like of mitochondrial related diseases such as cancer and the like, and meets clinical and scientific research requirements.

The invention discloses a preparation method and application of a coumarin-modified mitochondria-targeted fluorescent semi-sandwich structure iridium and ruthenium complex. The structural formula of the complex is as shown in formula (I). By introducing a coumarin group, the complex is endowed with fluorescence characteristics, and the complex can target mitochondria, has good anti-cancer activity and tracing function, can be selectively accumulated in cancer cell mitochondria to induce apoptosis, and can be used for preparing a fluorescent probe by virtue of the self-luminescence property. Researchers are helped to track intracellular transport distribution of drugs in real time, interaction between the drugs and biological target molecules is monitored, and an important research means is provided for revealing drug action mechanisms and targets. The preparation method disclosed by the invention is high in synthesis efficiency, and the prepared target complex has imaging capability and anti-cancer characteristic at the same time and is expected to become a novel multifunctional diagnosis and treatment reagent.

The invention discloses a cancer focus identification method, device and equipment and a storage medium, and relates to the technical field of biomedicine, and the method comprises the steps: collecting single cell transcriptome data of various cancer types, and carrying out the dimension reduction clustering of the filtered single cell transcriptome data; carrying out cell annotation on clustered cell groups, extracting epithelial cell groups, carrying out inter-group differential expression gene analysis, obtaining significantly up-regulated genes in each cancer type, and constructing a generic cancer cell characteristic gene set; carrying out pathological annotation on pathological sections of the spatial transcriptome data, and carrying out malignant scoring on each spot by utilizing a generic cancer cell characteristic gene set; and based on the pathological annotation label and the malignant score of each spot, constructing a cancer focus prediction model, and predicting a cancer focus spatial position in the spatial transcriptome data. According to the invention, the position of the cancerous lesion in the space transcriptome can be rapidly identified, and the tumor invasion leading edge area can be identified based on the cancerous lesion space positioning and the hexagonal system of the space transcriptomics.

The invention discloses an application of scurriboside B or a derivative thereof in preparation of a medicine for treating gastric cancer. The structure of the scurriboside B is shown in the specification. The Sanbao lignin B or the derivative of the Sanbao lignin B down-regulates expression of invasion and metastasis related protein, inhibits migration and invasion of gastric cancer cells, reduces the risk of tumor distant metastasis and blocks malignant progression of gastric cancer by regulating an EMT related signal channel. Aiming at the pain points of low proportion of HER2 positive patients, easy generation of drug resistance of targeted drugs, limited immune treatment benefit crowds and the like in current gastric cancer treatment, the Sancurbatin B as a brand new natural anti-tumor active component provides a new candidate target and direction for research and development of anti-gastric cancer drugs. The compound not only can be independently developed into an anti-gastric cancer drug, but also can be used in combination with chemotherapy, targeted therapy or immunotherapy drugs to synergistically improve the treatment effect, and has extremely high clinical transformation value and market application potential.